Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019:1148:255-277.
doi: 10.1007/978-981-13-7709-9_12.

Clinical Applications of Hyaluronidase

Affiliations
Review

Clinical Applications of Hyaluronidase

Gregor Cornelius Weber et al. Adv Exp Med Biol. 2019.

Abstract

Hyaluronidases are enzymes that degrade hyaluronic acid, which constitutes an essential part of the extracellular matrix. Initially discovered in bacteria, hyaluronidases are known to be widely distributed in nature and have been found in many classes including insects, snakes, fish and mammals. In the human, six different hyaluronidases, HYAL1-4, HYAL-P1 and PH-20, have been identified. PH-20 exerts the strongest biologic activity, is found in high concentrations in the testicles and can be localized on the head and the acrosome of human spermatozoa. Today, animal-derived bovine or ovine testicular hyaluronidases as well as synthetic hyaluronidases are clinically applied as adjuncts to increase the bioavailability of drugs, for the therapy of extravasations, or for the management of complications associated with the aesthetic injection of hyaluronic acid-based fillers. Further applications in the fields of surgery, aesthetic medicine, immunology, oncology, and many others can be expected for years to come. Here, we give an overview over the molecular and cellular mode of action of hyaluronidase and the hyaluronic acid metabolism, as well as over current and potential future clinical applications of hyaluronidase.

Keywords: Bioavailability; Extravasation; Filler; Hyaluronan; Hyaluronic acid; Hylase; Spreading factor.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ahmed S, Ahmed OA (2004) Hyaluronidase revisited-a single injection technique for harvesting split thickness skin grafts under local anaesthesia. Br J Plast Surg 57:589–591 - PubMed
    1. Albanell J, Baselga J (2000) Systemic therapy emergencies. Semin Oncol 27:347–361 - PubMed
    1. Alberts DS, Dorr RT (1991) Case report: topical DMSO for mitomycin-C-induced skin ulceration. Oncol Nurs Forum 18:693–695 - PubMed
    1. Allen CH, Etzwiler LS, Miller MK et al (2009) Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics 124:e858–e867 - PubMed
    1. Aruffo A, Stamenkovic I, Melnick M et al (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303–1313 - PubMed

LinkOut - more resources